載入...
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
With the emergence of effective immunotherapeutics, which nevertheless harbor the potential for toxicity and are expensive to use, biomarkers are urgently needed for identification of cancer patients who respond to treatment. In this clinical-epidemiological study of 202 cancer patients treated with...
Na minha lista:
| 發表在: | Oncoimmunology |
|---|---|
| Main Authors: | , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Taylor & Francis
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4404794/ https://ncbi.nlm.nih.gov/pubmed/25949903 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/2162402X.2014.989771 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|